PathAI
Loyal, a platform helping health systems and hospitals connect with patients, and AI-enabled pathology company PathAI adds new leadership.
The multinational pharma company will now be able to access Tempus' de-identified patient data.
The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.
The five-year deal will utilize PathAI's algorithms for translational research and clinical diagnostics.
The partnership will initially be used to distribute PathAI’s research-use-only algorithm focusing on immuno-oncology.
The companies will combine their complementary pathology tools to leverage services for tech-enabled diagnostics, drug discovery and patient care.
Also: Artificial scores $21.5M for lab automation, medication adherence platform emocha Health completes oversubscribed Series A and DeepScribe raises $5.2M in seed funding.
A new innovation center called the Biome and numerous internal efforts paint a picture of a digital-focused game plan.